Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Background:
- Researchers have developed an experimental cancer treatment called cell therapy. White
blood cells called lymphocytes are taken from a tumor, grown in large numbers in the lab, and
then given back to the patient. Interleukin-15, given to the patient after the cells (now
called Young tumor-infiltrating lymphocytes of Young TIL cells) are replaced, helps the cells
to grow and boosts the immune system. This process changes your normal cells into cells that
are able to recognize your tumor has been studied in the lab. These cells can destroy tumor
cells in the test tube, but scientists want to see if they work inside the body.
Objectives:
-To test the effectiveness of lymphocytes drawn from tumor cells combined with interleukin-15
in treating metastatic melanoma.
Eligibility:
- Patients must be 18 - 66 years of age and have a diagnosis of metastatic melanoma.
- They will have heart and lung function tests, lab tests, and imaging procedures.
- Patients may not have conditions such as active systemic infections, blood clotting
disorders, or other active major medical illnesses.
- Patients may not be pregnant or nursing.